These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30616487)

  • 1. Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder.
    Peeler M; Fiscella K; Terplan M; Sufrin C
    J Correct Health Care; 2019 Jan; 25(1):4-14. PubMed ID: 30616487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Management of Incarcerated Pregnant Women With Opioid Use Disorder.
    O'Connor A; Bowling N
    J Correct Health Care; 2020 Jan; 26(1):17-26. PubMed ID: 31960750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of opioid use disorder in pregnancy.
    Rodriguez CE; Klie KA
    Semin Perinatol; 2019 Apr; 43(3):141-148. PubMed ID: 30755340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medications for opioid use disorder in pregnancy in a state women's prison facility.
    Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE
    Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with buprenorphine versus methadone use in pregnancy.
    Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N
    Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
    Wilder C; Lewis D; Winhusen T
    Drug Alcohol Depend; 2015 Apr; 149():225-31. PubMed ID: 25735465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 28-year-old Woman With Opioid Use Disorder Delivers Healthy Baby While in Custody: Addressing Forced Detox.
    Gray J; Saia K; Walley AY
    J Addict Med; 2019; 13(3):237-240. PubMed ID: 30379779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating perinatal opioid use disorder in rural settings: Challenges and opportunities.
    Higgins TM; Goodman DJ; Meyer MC
    Prev Med; 2019 Nov; 128():105786. PubMed ID: 31356827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Use Disorder in Pregnancy.
    Roper V; Cox KJ
    J Midwifery Womens Health; 2017 May; 62(3):329-340. PubMed ID: 28561914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
    Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
    Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting.
    Mitchell M
    J Correct Health Care; 2021 Sep; 27(3):210-214. PubMed ID: 34388040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 20. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.